Literature DB >> 6618531

Genetic studies on natural resistance to Moloney lymphoma (YAC) isografts. I. Introduction of a non-H-2-linked resistance gene on strain A/Sn background.

L Ahrlund-Richter, G Klein, E Klein.   

Abstract

YAC is a Moloney-virus-induced lymphoma of strain A/Sn origin that is highly sensitive to natural killing (NK) in vitro and NK-mediated hybrid resistance in vivo. Previous studies have shown that hybrid resistance is under polygenic control that includes both H-2-linked and non-H-2-linked factors. For further analysis on the genetics and immunology of hybrid resistance, we are at present developing congenic resistant lines on an A/Sn strain background. Following an outcross to a strain that conveys strong hybrid resistance on the F1 offspring, the mice are challenged with small viable inocula of YAC. Survivors are backcrossed to A/Sn. This is followed by repeated YAC challenge and backcrossing. We now report the successful establishment of a first resistant strain, designated A.LRA. It is relatively resistant to small inocula of YAC cells due to a single, non-H-2-linked dominant gene introduced from the C57L strain.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6618531     DOI: 10.1007/bf00952961

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  12 in total

1.  Histocompatibility genes of the mouse. II. Production and analysis of isogenic resistant lines.

Authors:  G D SNELL; R B JACKSON
Journal:  J Natl Cancer Inst       Date:  1958-11       Impact factor: 13.506

2.  Genetic variation in antibody response and natural killer cell activity against a Moloney virus-induced lymphoma (YAC).

Authors:  B Asjö; R Kiessling; G Klein; S Povey
Journal:  Eur J Immunol       Date:  1977-08       Impact factor: 5.532

3.  Progressive loss of H-2 antigens with concomitant increase of cell-surface antigen(s) determined by Moloney leukemia virus in cultured murine lymphomas.

Authors:  M Cikes; S Friberg; G Klein
Journal:  J Natl Cancer Inst       Date:  1973-02       Impact factor: 13.506

4.  Hybrid resistance to BALB/c plasmacytomas. I. Resistance to MPC-11 controlled by a locus not linked to H-2.

Authors:  M C Walker; J M Phillips-Quagliata
Journal:  J Immunol       Date:  1979-04       Impact factor: 5.422

5.  The role of humoral immunity and the contribution of the F1 anti-parental effect in the rejection of a Moloney leukemia virus-induced lymphoma graft.

Authors:  B Asjö; E Klein; E M Fenyö; G Klein
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

6.  Non-T-cell resistance against a mouse Moloney lymphoma.

Authors:  R Kiessling; G Petrányi; G Klein; H Wigzell
Journal:  Int J Cancer       Date:  1976-02-15       Impact factor: 7.396

7.  Semisyngeneic hybrid resistance to murine teratocarcinoma cells.

Authors:  G A Bishop; W F Dove
Journal:  Immunogenetics       Date:  1980       Impact factor: 2.846

8.  Genetic variation of in vitro cytolytic activity and in vivo rejection potential of non-immunized semi-syngeneic mice against a mouse lymphoma line.

Authors:  R Kiessling; G Petranyi; G Klein; H Wigzel
Journal:  Int J Cancer       Date:  1975-06-15       Impact factor: 7.396

9.  'Hybrid resistance' against parental tumors: One or several genetic patterns?

Authors:  G Klein; G O Klein; K Kärre; R Kiessling
Journal:  Immunogenetics       Date:  1978-12       Impact factor: 2.846

10.  Anti-Friend virus antibody is associated with recovery from viremia and loss of viral leukemia cell-surface antigens in leukemic mice. Identification of Rfv-3 as a gene locus influencing antibody production.

Authors:  D Doig; B Chesebro
Journal:  J Exp Med       Date:  1979-07-01       Impact factor: 14.307

View more
  1 in total

1.  Genetic studies on natural resistance to Moloney lymphoma (YAC) isografts. II. Selective introduction of resistance genes, derived from C57BL/6 or CBA, to strain A/Sn background.

Authors:  L Ahrlund-Richter; C Nordstedt; G Klein; E Klein
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.